ENGINE: a Phase III randomized placebo controlled study of enzastaurin/R-CHOP as frontline therapy in high-risk diffuse large B-cell lymphoma patients with the genomic biomarker DGM1.

doi:10.2217/fon-2020-0176

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

ENGINE: a Phase III randomized placebo controlled study of enzastaurin/R-CHOP as frontline therapy in high-risk diffuse large B-cell lymphoma patients with the genomic biomarker DGM1.

Future oncology (London, England) - 1 May 2020

Nowakowski Grzegorz S, Zhu Jun, Zhang Qingyuan, Brody Joshua, Sun Xiuhua, Maly Joseph, Song Yuqin, Rizvi Syed, Song Yongping, Lansigan Frederick, Jing Hongmei, Cao Junning, Lue Jennifer K, Luo Wen, Zhang Lei, Li Ling, Han Isabel, Sun Joan, Jivani Manoj, Liu Young, Heineman Thomas, Smith Stephen D

Abstract excerpt

While combination of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) cures most patients with diffuse large B-cell lymphoma (DLBCL), those with high-risk international prognostic index disease have inferior survival. Enzastaurin as a potent inhibitor of PKC-β and PI3K/AKT pathway suppressor has been tested in many clinical trials including two key studies in DLBCL: Phase III...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Clinical Trials, Phase III as Topic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cyclophosphamide

Share to Doxorubicin

Share to Lymphoma, Large B-Cell, Diffuse

Share to Prednisone

Share to Randomized Controlled Trials as Topic

Share to Rituximab

Share to Vincristine

Source

Open in PubMed

Identifiers

PMID: 32250167
DOI: 10.2217/fon-2020-0176

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ENGINE: a Phase III randomized placebo controlled study of enzastaurin/R-CHOP as frontline therapy in high-risk diffuse large B-cell lymphoma patients with the genomic biomarker DGM1.PMID 32250167Read ↗

Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma.Semantic proximity Read ↗

Genome-Wide Association Study of Event-Free Survival in Diffuse Large B-Cell Lymphoma Treated With ImmunochemotherapySemantic proximity Read ↗

CUDC-907 in relapsed/refractory diffuse large B-cell lymphoma, including patients with MYC-alterations: results from an expanded phase I trial.Semantic proximity Read ↗

Multiparameter analysis of homogeneously R-CHOP-treated diffuse large B cell lymphomas identifies CD5 and FOXP1 as relevant prognostic biomarkers: report of the prospective SAKK 38/07 study.Semantic proximity Read ↗

The treatment of Burkitt lymphoma in adults.Semantic proximity Read ↗

Molecularly Adapted Antitumor Therapy for Newly Diagnosed Diffuse Large B-Cell Lymphoma: Two-Year Follow-Up ResultsSemantic proximity Read ↗

Idelalisib-rituximab induces durable remissions in TP53 disrupted B-PLL but results in significant toxicity: updated results of the UK-wide compassionate use programme.Semantic proximity Read ↗

Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma.Semantic proximity Read ↗

A53-Adapted Decitabine-Containing R-CHOP in Newly Diagnosed Diffuse Large B-Cell Lymphoma Defined by LymphGen: Preliminary Results of a Prospective Proof-of-Concept StudySemantic proximity Read ↗

Efficacy and safety of Orelabrutinib-based regimens in diffuse large B-cell lymphoma: A single-center retrospective analysisSemantic proximity Read ↗

Real-world Outcomes of Diffuse Large B-cell Lymphoma Treated with frontline R-CHOP(-like) regimens in an Asian Multi-ethnic PopulationSemantic proximity Read ↗

Clinical efficacy and molecular biomarkers in a phase II study of tucidinostat plus R-CHOP in elderly patients with newly diagnosed diffuse large B-cell lymphoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.